Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI
Intra-Cellular Therapies (ITCI) Stock Price & Analysis
726 Followers
ITCI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$42.01 - $66.56
Previous Close$60.2
Volume469.09K
Average Volume (3M)870.24K
Market Cap
$5.77B
Enterprise Value$5.25B
Total Cash (Recent Filing)$540.46M
Total Debt (Recent Filing)$18.49M
Price to Earnings (P/E)-25.0
Beta0.39
Next Earnings
Aug 08, 2023EPS Estimate
-$0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.41
Shares Outstanding95,925,601
10 Day Avg. Volume655,126
30 Day Avg. Volume870,237
Standard Deviation0.36
R-Squared0.03
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)9.32
Price to Sales (P/S)60.59
Price to Cash Flow (P/CF)-24.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue16.93
Enterprise Value/Gross Profit20.97
Enterprise Value/Ebitda-21.94
Forecast
1Y Price Target
$74.42Price Target Upside23.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Intra-Cellular Therapies News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ITCI FAQ
What was Intra-Cellular Therapies’s price range in the past 12 months?
Intra-Cellular Therapies lowest stock price was $42.01 and its highest was $66.56 in the past 12 months.
What is Intra-Cellular Therapies’s market cap?
Currently, no data Available
When is Intra-Cellular Therapies’s upcoming earnings report date?
Intra-Cellular Therapies’s upcoming earnings report date is Aug 08, 2023 which is in 73 days.
How were Intra-Cellular Therapies’s earnings last quarter?
Intra-Cellular Therapies released its earnings results on May 04, 2023. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.606 by $0.146.
Is Intra-Cellular Therapies overvalued?
According to Wall Street analysts Intra-Cellular Therapies’s price is currently Undervalued.
Does Intra-Cellular Therapies pay dividends?
Intra-Cellular Therapies does not currently pay dividends.
What is Intra-Cellular Therapies’s EPS estimate?
Intra-Cellular Therapies’s EPS estimate is -$0.61.
How many shares outstanding does Intra-Cellular Therapies have?
Intra-Cellular Therapies has 95,925,600 shares outstanding.
What happened to Intra-Cellular Therapies’s price movement after its last earnings report?
Intra-Cellular Therapies reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.606. Following the earnings report the stock price went down -2.024%.
Which hedge fund is a major shareholder of Intra-Cellular Therapies?
Among the largest hedge funds holding Intra-Cellular Therapies’s share is Deerfield Management Company, LP. It holds Intra-Cellular Therapies’s shares valued at 40M.
---
Intra-Cellular Therapies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.42 (23.62% Upside)
$74.42 (23.62% Upside)
Blogger Sentiment
Bullish
ITCI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 335.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 3.5%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.52%
12-Months-Change
Fundamentals
Return on Equity
-32.13%
Trailing 12-Months
Asset Growth
-16.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Intra-Cellular Therapies
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
---
Top 5 ETFs holding ITCI
Vanguard Health Care ETF
$18.51M
Fidelity MSCI Health Care Index ETF
$2.85M
iShares NASDAQ US Biotechnology UCITS ETF
$2.85M
Innovator IBD 50 ETF
$2.25M
Fidelity Nasdaq Composite Index ETF
$1.31M
Up to five ETFs with an Outperform Smart Score that hold ITCI. The ETFs are listed according to market value of ITCI within the ETF
---
---